{"title":"核因子κ b配体受体激活剂抗体对胶原抗体性关节炎小鼠炎症和软骨降解的影响。","authors":"Sakie Funato, Akihiro Matsunaga, Koei Oh, Yoichi Miyamoto, Kentaro Yoshimura, Junichi Tanaka, Dai Suzuki, Risa Uyama, Hiroaki Suzuki, Kenji Mishima, Masanori Nakamura, Osamu Namiki, Kazuyoshi Baba, Katsunori Inagaki, Ryutaro Kamijo","doi":"10.1186/s12952-014-0018-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is an inflammatory disease that leads to destruction of both articular cartilage and bone tissues. In rheumatic joints, synoviocytes and T-lymphocytes as well as bone cells produce the receptor activator of nuclear factor κ-B (RANK) ligand (RANKL), which binds to RANK on the surface of osteoclasts and their precursor cells to induce differentiation and activation of osteoclasts. Hence, inhibition of RANKL may be a promising approach to suppress osteolysis in RA. On the other hand, RANKL production by lymphocytes indicates the possibility that its inhibition would be effective to suppress inflammation in RA. In addition, it has been reported that cathepsin K, a predominant cysteine protease in osteoclasts, is involved in cartilage destruction in RA model mice. Here, we evaluated the effects of an anti-RANKL antibody on inflammation in footpads and degradation of articular cartilage in RA model mice.</p><p><strong>Results: </strong>We induced arthritis in mice by injection of anti-type II collagen antibodies and lipopolysaccharide (LPS). Inhibition of RANKL by an anti-RANKL antibody (OYC1, Oriental Yeast, Tokyo, Japan) was confirmed by increased bone volume in the metaphysis of tibias. Swelling in either limb until day 14 was seen in 5 of 6 mice injected with anti-collagen antibodies and LPS without treatment with OYC1, while that was seen in 4 of 5 mice treated with OYC1. The average arthritis scores on day 14 in those groups were 2.17 and 3.00, respectively, indicating that OYC1 did not ameliorate inflammation in the limbs. Histological analyses indicated that OYC1 does not protect articular cartilage from destruction in mice with arthritis.</p><p><strong>Conclusions: </strong>Our present study failed to show the effectiveness of an anti-RANKL antibody to ameliorate inflammation in the limbs or protect articular cartilage from degradation in a collagen antibody-induced arthritis mouse model.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":"13 ","pages":"18"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12952-014-0018-0","citationCount":"2","resultStr":"{\"title\":\"Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.\",\"authors\":\"Sakie Funato, Akihiro Matsunaga, Koei Oh, Yoichi Miyamoto, Kentaro Yoshimura, Junichi Tanaka, Dai Suzuki, Risa Uyama, Hiroaki Suzuki, Kenji Mishima, Masanori Nakamura, Osamu Namiki, Kazuyoshi Baba, Katsunori Inagaki, Ryutaro Kamijo\",\"doi\":\"10.1186/s12952-014-0018-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is an inflammatory disease that leads to destruction of both articular cartilage and bone tissues. In rheumatic joints, synoviocytes and T-lymphocytes as well as bone cells produce the receptor activator of nuclear factor κ-B (RANK) ligand (RANKL), which binds to RANK on the surface of osteoclasts and their precursor cells to induce differentiation and activation of osteoclasts. Hence, inhibition of RANKL may be a promising approach to suppress osteolysis in RA. On the other hand, RANKL production by lymphocytes indicates the possibility that its inhibition would be effective to suppress inflammation in RA. In addition, it has been reported that cathepsin K, a predominant cysteine protease in osteoclasts, is involved in cartilage destruction in RA model mice. Here, we evaluated the effects of an anti-RANKL antibody on inflammation in footpads and degradation of articular cartilage in RA model mice.</p><p><strong>Results: </strong>We induced arthritis in mice by injection of anti-type II collagen antibodies and lipopolysaccharide (LPS). Inhibition of RANKL by an anti-RANKL antibody (OYC1, Oriental Yeast, Tokyo, Japan) was confirmed by increased bone volume in the metaphysis of tibias. Swelling in either limb until day 14 was seen in 5 of 6 mice injected with anti-collagen antibodies and LPS without treatment with OYC1, while that was seen in 4 of 5 mice treated with OYC1. The average arthritis scores on day 14 in those groups were 2.17 and 3.00, respectively, indicating that OYC1 did not ameliorate inflammation in the limbs. Histological analyses indicated that OYC1 does not protect articular cartilage from destruction in mice with arthritis.</p><p><strong>Conclusions: </strong>Our present study failed to show the effectiveness of an anti-RANKL antibody to ameliorate inflammation in the limbs or protect articular cartilage from degradation in a collagen antibody-induced arthritis mouse model.</p>\",\"PeriodicalId\":73849,\"journal\":{\"name\":\"Journal of negative results in biomedicine\",\"volume\":\"13 \",\"pages\":\"18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s12952-014-0018-0\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of negative results in biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12952-014-0018-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of negative results in biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12952-014-0018-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
背景:类风湿性关节炎(RA)是一种导致关节软骨和骨组织破坏的炎症性疾病。在风湿性关节中,滑膜细胞和t淋巴细胞以及骨细胞产生核因子κ-B (RANK)配体受体激活因子(RANKL),与破骨细胞及其前体细胞表面的RANK结合,诱导破骨细胞分化活化。因此,抑制RANKL可能是抑制RA骨溶解的一种有希望的方法。另一方面,淋巴细胞产生RANKL表明抑制RANKL可能有效抑制RA炎症。此外,据报道,组织蛋白酶K是破骨细胞中主要的半胱氨酸蛋白酶,参与RA模型小鼠的软骨破坏。在这里,我们评估了抗rankl抗体对RA模型小鼠脚垫炎症和关节软骨降解的影响。结果:通过注射抗II型胶原抗体和脂多糖(LPS)诱导小鼠关节炎。抗RANKL抗体(OYC1, Oriental Yeast, Tokyo, Japan)对RANKL的抑制作用通过胫骨干骺端骨体积的增加得到证实。注射抗胶原抗体和LPS的6只小鼠中有5只在未使用OYC1治疗的情况下出现四肢肿胀,直到第14天,而使用OYC1治疗的5只小鼠中有4只出现四肢肿胀。第14天,两组患者的平均关节炎评分分别为2.17分和3.00分,表明OYC1并没有改善肢体炎症。组织学分析表明,OYC1不能保护关节炎小鼠的关节软骨免受破坏。结论:在胶原抗体诱导的关节炎小鼠模型中,我们目前的研究未能显示抗rankl抗体改善四肢炎症或保护关节软骨免受降解的有效性。
Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.
Background: Rheumatoid arthritis (RA) is an inflammatory disease that leads to destruction of both articular cartilage and bone tissues. In rheumatic joints, synoviocytes and T-lymphocytes as well as bone cells produce the receptor activator of nuclear factor κ-B (RANK) ligand (RANKL), which binds to RANK on the surface of osteoclasts and their precursor cells to induce differentiation and activation of osteoclasts. Hence, inhibition of RANKL may be a promising approach to suppress osteolysis in RA. On the other hand, RANKL production by lymphocytes indicates the possibility that its inhibition would be effective to suppress inflammation in RA. In addition, it has been reported that cathepsin K, a predominant cysteine protease in osteoclasts, is involved in cartilage destruction in RA model mice. Here, we evaluated the effects of an anti-RANKL antibody on inflammation in footpads and degradation of articular cartilage in RA model mice.
Results: We induced arthritis in mice by injection of anti-type II collagen antibodies and lipopolysaccharide (LPS). Inhibition of RANKL by an anti-RANKL antibody (OYC1, Oriental Yeast, Tokyo, Japan) was confirmed by increased bone volume in the metaphysis of tibias. Swelling in either limb until day 14 was seen in 5 of 6 mice injected with anti-collagen antibodies and LPS without treatment with OYC1, while that was seen in 4 of 5 mice treated with OYC1. The average arthritis scores on day 14 in those groups were 2.17 and 3.00, respectively, indicating that OYC1 did not ameliorate inflammation in the limbs. Histological analyses indicated that OYC1 does not protect articular cartilage from destruction in mice with arthritis.
Conclusions: Our present study failed to show the effectiveness of an anti-RANKL antibody to ameliorate inflammation in the limbs or protect articular cartilage from degradation in a collagen antibody-induced arthritis mouse model.